Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
144 hedge funds and large institutions have $385M invested in Intercept Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 55 increasing their positions, 42 reducing their positions, and 23 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 42
9% more capital invested
Capital invested by funds: $353M → $385M (+$31.1M)
4% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 23
0% more funds holding
Funds holding: 144 → 144 (0)
17% less call options, than puts
Call options by funds: $10.1M | Put options by funds: $12.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$7.75M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.59M |
| 3 |
D.E. Shaw & Co
New York
|
+$6.28M |
| 4 |
Renaissance Technologies
New York
|
+$5.92M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
-$7.84M |
| 2 |
Morgan Stanley
New York
|
-$7M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.54M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.49M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$5.17M |
ICPT Hedge Fund Activity: Q1 2023 in Review
144 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2023, worth a combined $385M — up 8.8% from $353M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ICPT positions and 23 closed out — a net gain of 1 holder — while 55 added to existing stakes and 42 trimmed.
The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $7.75M. The largest seller was ExodusPoint Capital Management, cutting an estimated $7.84M.
- 144 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $385M of Intercept Pharmaceuticals, Inc. stock for Q1 2023, up 8.8% quarter-over-quarter.
- 24 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2023 and 23 closed out, a net change of +1 holder.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2023 was Pictet Asset Management (Switzerland), an estimated $7.75M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q1 2023 was ExodusPoint Capital Management, an estimated $7.84M sold.
Based on aggregated 13F filings for Q1 2023.